Session » Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 476

A Better Understanding of Childhood Sjögren Syndrome: Evaluation of the 2016 Acr/EULAR Classification Criteria for Use in Diagnosing Sjögren Syndrome in Children

9:00AM-11:00AM: Abstract Number: 473

A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 475

Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 480

Analyze Myositis with Ultrasound and Exercise (AMUSE) Kids- Initial Analysis of Longitudinal Data

9:00AM-11:00AM: Abstract Number: 468

Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 469

Clinical Characteristics and Treatment of 25 Children with Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy in China

9:00AM-11:00AM: Abstract Number: 471

Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 477

Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis

9:00AM-11:00AM: Abstract Number: 478

Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation

9:00AM-11:00AM: Abstract Number: 460

Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 466

Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR

9:00AM-11:00AM: Abstract Number: 479

Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 472

Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications

9:00AM-11:00AM: Abstract Number: 474

Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus

9:00AM-11:00AM: Abstract Number: 461

Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 463

Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 470

Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE

9:00AM-11:00AM: Abstract Number: 459

Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy

9:00AM-11:00AM: Abstract Number: 465

Seasonal Variation in Cutaneous Flares for Pediatric Lupus

9:00AM-11:00AM: Abstract Number: 481

Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 462

Steroid Use in Pediatric Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 482

The Association of Short-Term Ultraviolet Radiation Exposure and Calcinosis in Juvenile Dermatomyositis in the Childhood Arthritis & Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 464

The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort

9:00AM-11:00AM: Abstract Number: 467

The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry

9:00AM-11:00AM: Abstract Number: 458

Validation of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria Compared to the 1997 Acr Criteria and 2017 Candidate Weighted Criteria for Lupus in Pediatric Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].